Long-term Cancer Risk in Patients With Pediatric-Onset Inflammatory Bowel Diseases in the Canadian Population
Authors:
- 1 July 2020
- journal article
- research article
- Published by Elsevier in Gastroenterology
- Vol. 159 (1) , 386-387
Abstract
No abstract availableKeywords
Funding Information
- Pfizer Canada
- AbbVie
- Janssen Canada
- Takeda Pharmaceutical Company
- Ferring
- Merck Canada
- Children's Hospital Research Institute of Manitoba
This publication has 8 references indexed in Scilit:
- Childhood onset inflammatory bowel disease and risk of cancer: a Swedish nationwide cohort study 1964-2014BMJ, 2017
- Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel DiseaseGastroenterology, 2017
- Cancers Complicating Inflammatory Bowel DiseaseNew England Journal of Medicine, 2015
- Inflammatory Bowel Disease in Children of ManitobaJournal of Pediatric Gastroenterology and Nutrition, 2014
- Chronic intestinal inflammation: inflammatory bowel disease and colitis-associated colon cancerFrontiers in Immunology, 2012
- Cancer risk in patients with inflammatory bowel diseaseCancer, 2001
- Epidemiology of Crohn's Disease and Ulcerative Colitis in a Central Canadian Province: A Population-based StudyAmerican Journal of Epidemiology, 1999
- Increased risk of large-bowel cancer in Crohn's disease with colonic involvementThe Lancet, 1990